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Abstract
Background:  Mucosal antibodies have been suggested t o  h a v e  a  r o l e  i n  d e f e n c e  a g a i n s t
pneumococcal infections. We investigated here the ability of a seven-valent pneumococcal
conjugate vaccine, PncOMPC, to induce mucosal immune response.
Methods: Healthy Finnish children (n = 111), a subcohort of the Finnish Otitis Media Vaccine Trial,
were recruited and 56 of them were immunised with the PncOMPC at the age of 2, 4, and 6
months. At 12 months of age, 49 of them received the PncOMPC and 7 were vaccinated with the
pneumococcal polysaccharide vaccine (PncPS) as a booster. The control group of 55 children
received a hepatitis B vaccine at the same ages. Salivary anti-Pnc IgG, IgA, IgA1, and IgA2 antibodies
to serotypes 6B, 14, 19F, and 23F were measured in both groups at the age of 7 and 13 months.
Results: Salivary anti-Pnc IgG and IgA were detected more often in the PncOMPC than in the
control group. However, the difference between groups was significant only for 19F and 23F IgA
concentrations at the age of 7 months. At the age of 13 months, antibody concentrations did not
differ between PncOMPC and control groups. The rises in IgA concentrations between 7 and 13
months of age were mainly of subclass IgA1. Further, there is a clear trend that PncPS booster
induces higher salivary anti-Pnc PS antibody concentrations than the PncOMPC.
Conclusion: We found that PncOMPC can induce a mucosal IgA response. However, the actual
impact of mucosal antibodies in protection against pneumococcal infections is not clear.
Background
Streptococcus pneumoniae (Pnc) frequently colonises
mucosal epithelium at nasopharynx without causing any
symptoms [1]. The carriage rate varies depending on the
age, being highest in children under two years of age [2].
Further, the prevalence of pneumococcal carriage is higher
in developing than developed countries [3]. Although the
pneumococcal carriage is often harmless, it may lead to a
local disease, e.g. to acute otitis media (AOM), sinusitis or
to an invasive disease like pneumonia, meningitis or sep-
sis [3].
The main mechanism of defence against pneumococcus
are anticapsular antibodies, which help in the phagocyto-
sis or which can counteract acquisition of pneumococcus
probably by preventing adhesion to the mucosal surface
Published: 27 May 2005
BMC Infectious Diseases 2005, 5:41 doi:10.1186/1471-2334-5-41
Received: 08 February 2005
Accepted: 27 May 2005
This article is available from: http://www.biomedcentral.com/1471-2334/5/41
© 2005 Nurkka et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2005, 5:41 http://www.biomedcentral.com/1471-2334/5/41
Page 2 of 8
(page number not for citation purposes)
[4]. In serum the predominant immunoglobulin class is
IgG. The salivary IgG is mainly derived from serum by
leakage across capillaries and entering saliva through gin-
gival crevices. However, some local production of IgG
may take place [5,6]. At mucosal membranes IgA is the
main immunoglobulin class and it is found most often in
the secretory form (sIgA). The role of serum IgG in the
defence against pneumococcus is obvious; IgG can acti-
vate complement efficiently and further lead to phagocy-
tosis of bacteria. The function of mucosal antibodies in
humans is less clear. However, there are several pieces of
evidence, which suggest that they do have a role in the
defence. The presence of pneumococcus in nasopharynx
induces salivary antibodies against pneumococcal pro-
teins and polysaccharides already in infants [7,8], and
pneumococcal conjugate vaccines evoke mucosal
immune response [5,9-15]. In addition to invasive disease
and pneumonia, pneumococcal conjugate vaccines pre-
vent also local infections like AOM and carriage [16-22].
Further, in an animal model mucosal antibodies pre-
vented the acquisition of pneumococcus [23].
At the moment there is only one licensed pneumococcal
conjugate vaccine, PncCRM. The vaccine contains seven
pneumococcal capsular polysaccharides (PS) conjugated
to a non-toxic variant form of diphtheria toxin (CRM197).
The Kaiser Permanente Efficacy Trial in the USA showed
that PncCRM is highly protective, 97.4% (95% CI 88.7 to
99.9%), against invasive pneumococcal disease caused by
vaccine serotypes [16]. Among American Indian children,
which are a high risk population for pneumococcal infec-
tion, the intention-to-treat total primary efficacy of Pnc-
CRM against invasive disease was 82.6% (95% CI 21.4 to
96.1%) [24]. The efficacy of a 9-valent PncCRM in HIV-
infected and uninfected children has been studied in
Soweto, South-Africa [25]. The vaccine prevented there
83% (95% CI 39–97%) of invasive pneumococcal infec-
tions due to vaccine serotypes in HIV-uninfected children.
The respective number was 65% (95% CI 24–86%) in
HIV-infected children.
In the Finnish Otitis Media (FinOM) Vaccine Trial, two
pneumococcal conjugate vaccines, PncCRM and
PncOMPC, were investigated in parallel regarding the effi-
cacy against AOM using hepatitis B vaccine (HBV) as a
control for both arms. The efficacy of the PncCRM vaccine
was 57% (95% CI 44 to 67%) [19] and of the PncOMPC
vaccine 56% (95% CI 44 to 66%) [22] against AOM
caused by the vaccine serotypes. In the setting of the
FinOM Vaccine Trial we have had a possibility to evaluate
both the serum [19,22] and mucosal immunity [10] as
surrogates of vaccine efficacy [26].
The aim of this study was to measure the mucosal anti-
body responses after vaccination with 3 or 4 doses of
either the PncOMPC or the control vaccine. Measurement
of anti-Pnc antibodies against serotypes 6B, 14, 19F and
23F were selected because these types were most com-
monly associated with AOM in the FinOM studies
[10,19,27]. We compared the prevalence and concentra-
tions of salivary antibodies at 7 and 13 months of age in
the PncOMPC and control group. We also explored the
effect of pneumococcal polysaccharide vaccine (PncPS) as
a booster. The data on salivary antibody in the PncCRM
group has been reported separately [10].
Methods
Vaccines, vaccinees and vaccinations
PncOMPC (Merck & Co., Inc., West Point, PA) is a heptav-
alent pneumococcal conjugate vaccine containing 5 µg of
capsular PS of the serotype 6B, 3 µg of type 23F, 2 µg of
types 18C and 19F, 1.5 µg of type 9V, and 1 µg of types 4
and 14 each conjugated individually to an outer mem-
brane protein complex (OMPC) of Neisseria meningitidis
serogroup B. Aluminium was used as an adjuvant and thi-
omersal as a preservative. Pneumovax® (Merck & Co., Inc.)
is a 23-valent pneumococcal PS vaccine (PncPS), contain-
ing 25 µg of each capsular PS. HBV (Recombivax ™ Merck
& Co., Inc.) was used as a control vaccine. One dose of
HBV vaccine contains 5 µg of hepatitis B surface antigen.
The design of the FinOM Vaccine Trial has been described
previously [19,22]. In this study we had a subcohort of
111 infants. 56 children were randomised to receive the
PncOMPC vaccine at the age of 2, 4, and 6 months. At 12
months of age, 49 of them were vaccinated with the
PncOMPC and 7 with the PncPS as a booster vaccine. The
control group of 55 children received HBV at the same
ages.
Additionally, the children received a combined diphthe-
ria-tetanus-whole cell pertussis and Haemophilus influen-
zae  type b conjugate vaccine (Tetramune®, Wyeth
Pharmaceuticals) at 2, 4, 6, and 24 months, inactivated
polio vaccine (Imovax®, Aventis Pasteur) at 7, 12, and 24
months and measles-mumps-rubella (MMR®II, Merck &
Co., Inc.) at 18 months of age.
Sampling
Unstimulated saliva samples were taken at the age of 7 (n
= 111) and 13 (n = 107) months. Mothers were advised
not to breast feed infants during one hour before saliva
sampling. Up to 2 ml of saliva was collected with a gentle
aspiration using electronic suction device and samples
were immediately frozen at -70°C. Before analysis the
samples were centrifuged for 10 minutes with 15 000 rpm
and the supernatant was used for analyses of anti-Pnc PS
antibodies. The saliva samples were thawed only once.
The volume of the sample was not always sufficient for all
analyses.BMC Infectious Diseases 2005, 5:41 http://www.biomedcentral.com/1471-2334/5/41
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Measurement of antibodies
Enzyme immunoassay (EIA) for saliva samples
IgA, IgA1, IgA2, and IgG antibodies to serotypes 6B, 14,
19F and 23F were measured by EIA as described previ-
ously [5,10,11,14].
Before calculation of concentrations, optical density (OD)
readings from the PBS wells were subtracted from the anti-
gen plates. For IgA and IgG results OD values of ≥ 0.05 (≥
2 standard deviations of the blank) were regarded as pos-
itive. The concentrations of IgA and IgG were calculated in
nanograms per millilitre (ng/ml) of saliva by using the 89-
SF serum as a reference. The detection limit was 5 ng/ml
for both IgA and IgG assays and for all serotypes. Samples
with undetectable IgA and IgG were assigned a value 1.7
ng/ml; half a log less than the detection limit. The IgA1
and IgA2 results are presented as EIA units/ml calculated
using 89-SF as a reference with a given calibration factor
[28]. The detection limit of IgA1 and IgA2 assays for all the
serotypes was 1.3 units/ml; and samples with undetecta-
ble IgA1 and IgA2 concentrations were given a value 0.65
units/ml.
Statistical methods
Results are given as geometric mean antibody concentra-
tions (GMC) with 95% confidence intervals (CI). Differ-
ences in antibody concentrations in saliva samples
between different ages were analysed with Wilcoxon
Signed Ranks Test. Kruskal-Wallis test was used to com-
pare differences between PncOPMC and HBV groups. Pro-
portions of children having anti-Pnc antibodies in saliva
were compared with Yates-corrected chi square test (χ2-
test) or with Fisher's two-tailed exact test. Differences were
considered significant when p-value was <0.05. The sam-
ple size was not specifically determined for this study.
Results
Anti-pneumococcal IgG in saliva
Anti-Pnc PS IgG was detected at the age of both 7 and 13
months very rarely, and there were no differences either in
the proportion of positive samples or concentration
between the PncOMPC and control groups except for
serotype 14 at 13 months; there were more anti-Pnc PS
IgG positive samples in the PncOMPC than in the control
group (Table 1).
A small group of 7 children received PncPS vaccine as a
booster instead of PncOMPC at the age of 12 months. Fur-
ther, the volume of saliva was not sufficient for all the EIA
analyses. However, there was a clear trend that the PncPS
boosting induced more often IgG to the saliva than the
PncOMPC boosting (Table 1).
Anti-pneumococcal IgA in saliva
At the age of 7 months, anti-Pnc PS IgA was detected more
often and the concentrations were higher in the
PncOMPC than in the control group for all four serotypes
(Table 2, Fig 1). However, the difference was statistically
significant only for serotypes 19F (both the number of
positive samples and concentration) and 23F (concentra-
Table 1: Salivary anti-Pnc PS IgG antibodies in the PncOMPC, PncOMPC+PncPS booster and control groups; number and the 
proportion of positive samples at the age of 7 and 13 months.
Pnc serotype Age IgG
PncOMPC group Control group
N, samples Number positive (%) N, samples Number positive (%)
6B 7 mo 56 1 (2) 55 0
13 mo (PncOMPC booster) 44 3 (7) 55 0
13 mo (PncPS booster) 6 1 (17) NA
14 7 mo 56 2 (4) 55 2 (4)
13 mo (PncOMPC booster) 44 6 (14)a 55 1 (2)
13 mo (PncPS booster) 6 3 (50) NA
19F 7 mo 56 2 (4) 54 5 (9)
13 mo (PncOMPC booster) 44 6 (14) 55 2 (4)
13 mo (PncPS booster) 5 3 (60) NA
23F 7 mo 56 1 (2) 54 1 (2)
13 mo (PncOMPC booster) 44 0 55 1 (2)
13 mo (PncPS booster) 6 0 NA
a statistical difference in the number of positive samples between PncOMPC and control groups, p = 0.04.BMC Infectious Diseases 2005, 5:41 http://www.biomedcentral.com/1471-2334/5/41
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tion). The geometric mean concentrations (GMCs) varied
between 2.3 and 5.7 ng/ml, and 1.9 and 3.1 ng/ml in the
PncOMPC and control groups, respectively (Fig 1).
At the age of 13 months, there were no statistical differ-
ences between the PncOMPC and the control group either
in the proportion of positive samples or in the anti-Pnc PS
IgA concentrations (Table 2, Fig 1). After the booster, the
GMCs ranged between 3.7 and 11.2 ng/ml, and 3.0 and
8.0 ng/ml in the PncOMPC and control group, respec-
tively. However, there was a statistical difference between
7 and 13 months of age in the anti-Pnc PS IgA concentra-
tions for serotype 23F in the PncCRM group and for sero-
types 6B, 19F and 23F in the HBV group.
PncPS booster induced higher anti-Pnc PS IgA concentra-
tions than the PncOMPC (Table 2, Fig 1). However, the
small number of samples in the PncPS group did not
allow any statistical analyses.
IgA1 and IgA2 subclasses
At the age of 7 months, IgA1 concentrations were mirror-
ing the total anti-Pnc serotype specific IgA (Fig 1) and
were significantly higher in the PncOMPC than in the
control group for serotypes 6B, 19F, and 23F. However, at
the age of 13 months, there were no statistical differences
between the groups. The IgA2 concentrations did not
differ between the groups either at the age of 7 or 13
months. Thus, rises in the antibody concentrations were
seen only for IgA1 (Fig 2).
Discussion
Salivary anti-Pnc polysaccharide antibodies, both IgG and
IgA, were detected only slightly more often in the
PncOMPC than in the control group. However, the pro-
portion of positive samples and the antibody concentra-
tions rose between 7 and 13 months of age in both groups
and the differences between the vaccine groups dimin-
ished. This suggests that children in both groups had
pneumococcal contacts which induced development of
mucosal antibodies. This is in accordance with the find-
ings that pneumococcal carriage induces salivary antibod-
ies in children [7], also regardless of the previous
pneumococcal vaccination status [29].
In addition to IgA, we measured also IgA subclass specific
antibody development. IgA1 is the predominant subclass
both in serum and saliva, IgA1:IgA2 ratios being roughly
9:1 in serum and 6:4 in saliva [30]. To improve their viru-
lence, some bacteria including pneumococcus have devel-
oped proteases, which degrade IgA1 antibodies [31].
Recently, IgA1-proteases have been found to be important
in the adherence of pneumococcus [32]. Due to method-
ological reasons the IgA1 and IgA2 concentrations
detected in this study can not be compared as the data are
given in EIA units that are not comparable. However, we
found that the changes and the difference in the IgA
concentrations were mainly due to changes in the IgA1
concentrations. This is in accordance with our previous
findings [11,33]. This suggests that both IgA1 and IgA2 are
Table 2: Salivary anti-Pnc PS IgA antibodies in the PncOMPC, PncOMPC+PncPS booster and control groups; number and the 
percentage of positive samples at the age of 7 and 13 months.
Pnc serotype Age IgA
PncOMPC group Control group
N, samples Number positive (%) N, samples Number positive (%)
6B 7 mo 56 17 (30) 55 9 (16)
13 mo (PncOMPC booster) 45 23 (51) 55 26 (47)
13 mo (PncPS booster) 7 5 (71) NA
14 7 mo 56 23 (41) 55 14 (25)
13 mo (PncOMPC booster) 45 19 (42) 55 16 (29)
13 mo (PncPS booster) 7 5 (71) NA
19F 7 mo 56 32 (57)a 55 17 (31)
13 mo (PncOMPC booster) 45 35 (78) 55 35 (64)
13 mo (PncPS booster) 7 7 (100) NA
23F 7 mo 56 11 (20) 55 3 (5)
13 mo (PncOMPC booster) 45 18 (40) 55 17 (31)
13 mo (PncPS booster) 7 5 (71) NA
a statistical difference in the number of positive samples between PncOMPC and control groups, p = 0.01.BMC Infectious Diseases 2005, 5:41 http://www.biomedcentral.com/1471-2334/5/41
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present, but the vaccine induces IgA1, which, unfortu-
nately, is susceptible to IgA proteases.
We have also reported the mucosal anti-Pnc PS antibodies
in the PncCRM arm of the FinOM Vaccine Trial [10].
Though the PncCRM induced more often and higher con-
centrations of salivary anti-Pnc PS antibodies than the
PncOMPC vaccine (all the samples were analysed together
at the same time), the basic message from the two studies
is the same. The data of this study and of the PncCRM arm
[10] suggest that parenteral immunization with pneumo-
coccal conjugate vaccines induce local IgA1 antibody for-
mation, but the antibodies persist only for a short period.
The concentrations of anti-Pnc PS IgA at 13 months and
in the PncCRM arm also at 4 to 5 years of age were very
similar in the pneumococcal vaccine and in the control
vaccine groups indicating that no remarkable natural
boosting of the vaccine-induced antibodies occurred [10].
IgG anti-Pnc PS antibodies were detected only rarely. The
highest prevalence was found in the small group of chil-
dren whose 4th pneumococcal vaccine dose at 12 months
was PncPS vaccine. This is in accordance with the serum
antibody concentrations that were significantly higher in
the PncPS-boosted than in the PncOMPC-boosted chil-
dren for all other serotypes except 23F [34].
Pneumococcal PS vaccine has been suggested to be used
as a booster after a primary series with a pneumococcal
conjugate vaccine. It is cheaper than the conjugate vaccine
available and induces higher serum antibody concentra-
Salivary anti-Pnc PS IgA concentrations (ng/ml) with 95% confidence intervals in the PncOMPC, PncOMPC+PncPS booster and  control groups at the age of 7 and 13 months Figure 1
Salivary anti-Pnc PS IgA concentrations (ng/ml) with 95% confidence intervals in the PncOMPC, PncOMPC+PncPS booster and 
control groups at the age of 7 and 13 months.
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Salivary anti-Pnc PS IgA1 and IgA2 concentrations (EIA units/ml) with 95% confidence intervals in the PncOMPC,  PncOMPC+PncPS booster and control groups at the age of 7 and 13 months Figure 2
Salivary anti-Pnc PS IgA1 and IgA2 concentrations (EIA units/ml) with 95% confidence intervals in the PncOMPC, 
PncOMPC+PncPS booster and control groups at the age of 7 and 13 months.BMC Infectious Diseases 2005, 5:41 http://www.biomedcentral.com/1471-2334/5/41
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tions than a conjugate booster [14,22,34]. However, a
conjugate vaccine as a booster can be favourable for the
persistence and quality of antibodies, because it stimu-
lates the formation of high-affinity clones of memory B-
cells [35]. There is also a possibility that PS booster may
cause depletion of memory cells [36]. Further, no signifi-
cant differences in the efficacy against AOM and recurrent
AOM have been found between PS and conjugate booster
[22,37]. We found in this study, that there is a clear trend
that the PS vaccine as a booster induces mucosal anti-
pneumococcal antibodies more often and in higher con-
centration than conjugate booster. The same effect of a
polysaccharide booster in salivary antibody concentra-
tions have been seen also previously [9,14]. However,
there may be differences in the quality of salivary antibod-
ies induced by the PS or conjugate vaccines.
Pneumococcal conjugate vaccines have been found to
induce both humoral and mucosal immunity. Further, the
vaccines have been found effective against invasive and
local pneumococcal infections. However, the antibody
concentrations or quality of antibodies needed for protec-
tion against disease and carriage are not known, even if
there has been a lot of discussion about the protective lev-
els [38,39]. Recently, a consensus about the estimate of
serological surrogate of protection against invasive pneu-
mococcal infections has been achieved. It is suggested that
the 0.35 µg/ml concentration of anti-Pnc PS IgG in serum
would predict the protection against pneumococcal infec-
tion at the population level http://www.who.int/biologi
cals/publications/en/
pneumococcal_conjugate_raccines_recomm_nov_2003.p
df. However, the value is a rough estimate and further, the
function of antibodies, both opsonophagocytic activity
and avidity, and immunological memory are also essen-
tial issues in serological immunity. In addition to the con-
centration and function of anti-pneumococcal antibodies
in serum, the importance and function of mucosal anti-
pneumococcal antibodies should be clarified. In the
FinOM Vaccine Trial the PncCRM induced more salivary
antibodies than the PncOMPC, but the efficacy of these
vaccines against AOM was similar. This raises a question,
which is the actual mechanism of protection? Anyway, we
know that pneumococcal carriage, infections and conju-
gate vaccines all induce mucosal antibodies. But we do
not know how important mucosal antibodies really are in
the defence against pneumococcal infections compared
with the antibodies in serum, and if mucosal immunisa-
tion would provide better local immune response.
Conclusion
We found that PncOMPC can induce a salivary IgA
response. However, the actual impact of mucosal antibod-
ies in protection against pneumococcal infections is not
clear.
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